Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1739]

Sotorasib shows superior PFS and ORR compared to docetaxel for NSCLC

Dr Silvia Novello - University of Turin, Turin, Italy

Sotorasib shows superior PFS and ORR compared to docetaxel for NSCLC ( Dr Silvia Novello - University of Turin, Turin, Italy )

ESMO 2022: Renal roundup

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

ESMO 2022: Renal roundup ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

ESMO 2022: Breast cancer highlights

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

ESMO 2022: Breast cancer highlights ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

Cabozantinib in combination w/ nivolumab and ipilimumab of IMDC intermediate or...

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

Cabozantinib in combination w/ nivolumab and ipilimumab of IMDC intermediate or poor risk significantly improved PFS vs PBO ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

Emerging systemic therapies in rare urothelial cancer variants

Dr Bradley McGregor - Dana-Farber Cancer Institute, Boston, USA

Emerging systemic therapies in rare urothelial cancer variants ( Dr Bradley McGregor - Dana-Farber Cancer Institute, Boston, USA )

Lenvatinib plus pembro for aRCC - update on the CLEAR study

Dr Bradley McGregor - Dana-Farber Cancer Institute, Boston, USA

Lenvatinib plus pembro for aRCC - update on the CLEAR study ( Dr Bradley McGregor - Dana-Farber Cancer Institute, Boston, USA )

Abemaciclib plus NSAI for HR+, HER2- advanced breast cancer - MONARCH 3 interim...

Prof Matthew P Goetz - Mayo Clinic, Rochester, USA

Abemaciclib plus NSAI for HR+, HER2- advanced breast cancer - MONARCH 3 interim data ( Prof Matthew P Goetz - Mayo Clinic, Rochester, USA )

Lasofoxifene vs fulvestrant for locally advanced/metastatic ER+/HER2- breast...

Prof Matthew P Goetz - Mayo Clinic, Rochester, USA

Lasofoxifene vs fulvestrant for locally advanced/metastatic ER+/HER2- breast cancer: ELAINE trial ( Prof Matthew P Goetz - Mayo Clinic, Rochester, USA )

Nivolumab and ipilimumab with tumour-infiltrating lymphocytes to treat triple...

Dr Iris Nederlof - The Netherlands Cancer Institute, Amsterdam, Netherlands

Nivolumab and ipilimumab with tumour-infiltrating lymphocytes to treat triple-negative breast cancer ( Dr Iris Nederlof - The Netherlands Cancer Institute, Amsterdam, Netherlands )

Atezolizumab improves on single-agent chemo for NSCLC not eligible for platinum...

Prof Siow-Ming Lee - University College London, London, UK

Atezolizumab improves on single-agent chemo for NSCLC not eligible for platinum-containing regimen ( Prof Siow-Ming Lee - University College London, London, UK )

Results from a phase 3 study of 1L atezolizumab vs single-agent chemotherapy in...

Prof Siow-Ming Lee - University College London, London, UK

Results from a phase 3 study of 1L atezolizumab vs single-agent chemotherapy in pts with NSCLC ( Prof Siow-Ming Lee - University College London, London, UK )

RADICALS-HD trial: androgen deprivation therapy with post-operative...

Prof Chris Parker - Institute of Cancer Research, Sutton, UK

RADICALS-HD trial: androgen deprivation therapy with post-operative radiotherapy to treat prostate cancer ( Prof Chris Parker - Institute of Cancer Research, Sutton, UK )

More from ecancer